Jump to top menu Jump to main menu Jump to content
Logo project carcinosarcoma of the uterus
Research project  |  PI H.J. van Beekhuizen

Carcinosarcoma of the Uterus

Status: ongoing

A prospective observational study in patients with carcinosarcoma of the uterus (CSU) in South-West Netherlands.

What we do

About our project

Background information

Carcinosarcomas of the uterus (CSU) are rare and highly aggressive malignancy that contain both malignant sarcomatous and carcinomatous element. The survival of women with advanced uterine carcinosarcoma carcinosarcoma is worse than survival of endometrioid or high-grade serous histologies. The incidence in the region South-West Netherlands is around 10 per year. Therapy is multimodal; consisting of surgery and/or chemotherapy and/or radiotherapy. Clear evidence to establish consensus guidelines for treatment - let alone evidence based guidelines - is lacking, because CSU are often excluded from major clinical studies on the effects of treatment. Therefore more research is very much needed, given that these patients have a poor prognosis.

Execution of the project

In 2016 we started a prospective registration study of all patients treated for CSU at the Erasmus MC: the Carcinosarcoma of the Uterus Study (CUS). We aim to disclose risk factors, treatment characteristics and quality-of-life (QoL) aspects. In addition in 2022 we started the CUS II study, in order to perform molecular analysis on a diverse set of samples (tumor tissue, liquid biopsies and pap smears)  to find new molecular markers in CSU.

Overall aim

With this study we aim to give insights in to the clinical and molecular characteristics of CSU and through this improve the prognosis of patients with CSU.

Our research focus

Prospective observational study

Clinical characteristics and survival of patients with CSU at our clinic will be reported. Patients included in the studies are asked to fill in standardized health-related QoL questionnaires. This is important, as patients with CSU have an poor prognosis even after extensive treatment. 

Molecular analysis

Molecular characteristics of a tumor are the cornerstone of the biology of cancer. By analyzing blood and tissue of patients with CSU we aim to gain more insight in molecular alterations in CSU by performing molecular analysis on tissue and blood of patients with CSU and find (bio)markers which can be linked to the clinical outcome or targets for adjuvant therapy



Collaboration within the Erasmus MC

  • Department of Pathology
  • Department of Oncology
  • Department of Radiotherapy  
  • Department of Development Biology 

Collaboration outside of the Erasmus MC

  • Methylomics, Rijswijk

Our team

Any questions?

Please contact our office if you have any questions or comments.

Contact form